Barinthus Biotherapeutics
NEWS
Vaccitech recently expanded from the U.K. to the U.S. CEO Bill Enright explains why.
Olink said the measurement of proteins at “population scale” provides the ability to improve the understanding of underlying mechanisms of diseases.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
It was another busy week for clinical trial news. Here’s a look.
The first week of November was marked by numerous clinical trial announcements. Here’s a look.
Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity.
April showers bring May dollars. Here’s whose cash gardens are really blooming this week in the life sciences world.
After quietly filing plans for an initial public offering earlier this month, U.K.-based Vaccitech raised $110.5 million in its IPO.
JOBS
IN THE PRESS